Fig. 1: SLC25A42 is upregulated and correlates with worse prognosis in patients with gastric cancer. | Cell Death & Disease

Fig. 1: SLC25A42 is upregulated and correlates with worse prognosis in patients with gastric cancer.

From: SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation

Fig. 1

The detection of SLC25A42 expression was carried out through qPCR (A, n = 40) and IHC (B, n = 385) analysis in paired GC and matched para-cancerous tissues. Scale bar, 20 μm. C, D CSM5 expression was also evaluated in a serial of widely used human GC cell lines (SNU-638, MKN-1, HGC-27, MKN-45, SNU-216) and a normal control gastric cell line (GES-1) through qPCR and Western blot analysis. Kaplan–Meier analysis was performed to compare the survival (E, overall survival; F, disease free survival) of GC patients with low-SLC25A42 and high-SLC25A42 levels. Overall survival (G) and post-progression survival (H) analysis of the gene chip expression database using the online Kaplan-Meier Plotter. I Overall survival analysis of TCGA database using the online UALCAN. *P < 0.05.

Back to article page